Maximum gain for Sun can go more than 15% from 1410/-, however downside risk should not be more than 10-15 %.
Hidden news-Once again Sun has done exceedingly well in second quarter.The sales rise in domestic mkt is to the tune of 28-32 %.Even recent ORG report has praised Sun once again as high value company poised in niche chronic therapy.
hmmm...not sure about next quarter results, But I did hear about a major stock recommendation this weekend to buy Sun Pharma for a target of approx 2000/-
Sun is in upswing.Next tgt is 1510 and for SPARC is 97.Over last few weeks, Sun is shown interest by both short term as well as long term players.Sun is indeed very much professional organisation which understands and institutes appropriate mktg tools.Cheers!
| NIFTY 
